A
68.50
-0.15 (-0.22%)
| Penutupan Terdahulu | 68.65 |
| Buka | 69.24 |
| Jumlah Dagangan | 670,205 |
| Purata Dagangan (3B) | 1,081,859 |
| Modal Pasaran | 3,960,866,816 |
| Harga / Jualan (P/S) | 105.90 |
| Harga / Buku (P/B) | 9.01 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -211.46% |
| Margin Operasi (TTM) | -847.56% |
| EPS Cair (TTM) | -2.99 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -79.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.76% |
| Nisbah Semasa (MRQ) | 4.93 |
| Aliran Tunai Operasi (OCF TTM) | -114.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.43 M |
| Pulangan Atas Aset (ROA TTM) | -16.69% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Arcellx, Inc. | Bercampur | Menurun |
AISkor Stockmoo
2.3
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.25 |
|
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 14.50% |
| % Dimiliki oleh Institusi | 102.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gilead Sciences, Inc. | 31 Dec 2025 | 6,720,803 |
| Nea Management Company, Llc | 30 Sep 2025 | 3,045,262 |
| Ra Capital Management, L.P. | 30 Sep 2025 | 3,036,527 |
| Perceptive Advisors Llc | 30 Sep 2025 | 2,468,353 |
| Sr One Capital Management, Lp | 31 Dec 2025 | 2,346,630 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 1,250,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 130.00 (Canaccord Genuity, 89.78%) | Beli |
| Median | 105.00 (53.29%) | |
| Rendah | 100.00 (UBS, 45.99%) | Beli |
| 100.00 (Wells Fargo, 45.99%) | Beli | |
| Purata | 110.00 (60.58%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 68.12 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 05 Feb 2026 | 105.00 (53.28%) | Beli | 66.94 |
| 08 Dec 2025 | 105.00 (53.28%) | Beli | 74.08 | |
| HC Wainwright & Co. | 04 Feb 2026 | 115.00 (67.88%) | Beli | 69.38 |
| UBS | 07 Jan 2026 | 100.00 (45.99%) | Beli | 65.01 |
| Wells Fargo | 22 Dec 2025 | 100.00 (45.99%) | Beli | 65.18 |
| Canaccord Genuity | 08 Dec 2025 | 130.00 (89.78%) | Beli | 74.08 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |